Andarine S-4 / GTx-007 — an early arylpropionamide discontinued for enobosarm

01 Names and programme fate

Andarine is S-4 / GTx-007, an arylpropionamide SARM. It is not enobosarm (S-22 / GTx-024), though both share a chemical family story. Development emphasis moved to enobosarm; andarine did not become an approved medicine. Open PubMed counts for andarine / GTx-007 / S-4 SARM queries were on the order of forty-five records at harvest, many analytical.

02 Preclinical pharmacology

Early pharmacology characterised tissue-selective anabolic activity on muscle and bone with reduced prostate stimulation relative to reference androgens in rodent models (Kearbey, Gao, and related S-4 papers; PMIDs including 17063395, 16099859, 15308613 among the harvest search hits). Those studies are animal pharmacology. They do not establish human efficacy or safety for physique use.

03 Clinical thinness

Unlike enobosarm and ligandrol, andarine lacks a landmark peer-reviewed lean-mass RCT island admitted in this harvest. Discontinuation in favour of enobosarm is the governing programme fact. In-vitro and specialised papers (for example mouse uterus effects, PMID 31319382; exploratory anti-carcinogenic in-vitro work) are edge literature, not clinical packages.

04 Vision adverse-effect lore — contested

Community sources repeatedly claim yellowish or night-vision disturbance with S-4. The Tavily harvest surfaced forums, video titles, and secondary web pages — not a clean randomised ocular-safety package. This monograph labels vision AE claims as contested / weakly sourced unless a primary clinical trial adverse-event table is admitted. Class SARM adverse-event reviews may mention ocular themes in passing; that is not the same as a confirmed andarine-specific trial finding.

05 Anti-doping detection

Mass-spectrometric characterisation and urinary metabolite papers for S-4 / andarine are a substantial fraction of the modern PubMed surface (e.g. PMID 20355219, 20623476). They confirm that the compound entered the doping-control problem set; they do not validate therapeutic use.

06 Regulatory status

Andarine is not FDA-approved. SARMs are WADA S1 prohibited. FDA consumer warnings on SARM body-building products apply to the retail context. LiverTox class language on cholestatic injury applies to consumer SARM exposure generally; andarine-specific DILI density is lower in the harvest than for ligandrol or RAD140, which is an absence of indexed cases, not a proof of hepatic safety.

07 Absences

No peer-reviewed Phase 2/3 physique or cachexia package for andarine was admitted. Vision AE remains contested. Grey-market product analytics are required before any case naming “S4” can be treated as clean exposure.

08 Harvest literature map

Deep-harvest strata for andarine: (1) early S-4 preclinical muscle/bone pharmacology; (2) programme shift to enobosarm; (3) anti-doping detection and metabolite characterisation; (4) contested vision AE lore from non-primary web sources. PubMed open count ~45 with many analytical hits. Exa surfaced Kearbey / Gao lineage papers and mouse uterus work. Tavily vision queries returned forums and secondary pages — kept out of the confirmed AE table.

How this document was assembled

Commissioned 5 August 2026 in the Adjacent Compounds / SARMs group and rewritten the same day after a deep research-API harvest (Tavily, Exa, PubMed E-utilities, ClinicalTrials.gov API v2, Camoufox for selected primary pages). Artefacts live under projects/adjacent_compounds_research_2026/deep_harvest/. HOUSE_STYLE governs presentation. PubMed-indexed references are NCBI-resolved.

Evidence handling

Study type is named in the reporting sentence. Animal and in-vitro results are not phrased as human outcomes. Sponsor press is secondary until peer-reviewed full text is admitted. Consumer case reports are grey-market exposure literature unless product analytics accompany the report. Cardarine is never called a SARM.

References

1. Gao W, Kearbey JD, Nair VA, Chung K, Parlow AF, Miller DD, et al.. Comparison of the pharmacological effects of a novel selective androgen receptor modulator, the 5alpha-reductase inhibitor finasteride, and the antiandrogen hydroxyflutamide in intact rats: new approach for benign prostate hyperplasia. Endocrinology. 2004;145(12):5420-8.
   PMID 15308613 · doi:10.1210/en.2004-0627 · PMC2098692
2. Gao W, Reiser PJ, Coss CC, Phelps MA, Kearbey JD, Miller DD, et al.. Selective androgen receptor modulator treatment improves muscle strength and body composition and prevents bone loss in orchidectomized rats. Endocrinology. 2005;146(11):4887-97.
   PMID 16099859 · doi:10.1210/en.2005-0572 · PMC2039881
3. Kearbey JD, Gao W, Narayanan R, Fisher SJ, Wu D, Miller DD, et al.. Selective Androgen Receptor Modulator (SARM) treatment prevents bone loss and reduces body fat in ovariectomized rats. Pharm Res. 2007;24(2):328-35.
   PMID 17063395 · doi:10.1007/s11095-006-9152-9 · PMC2039878
4. Leciejewska N, Jędrejko K, Gómez-Renaud VM, Manríquez-Núñez J, Muszyńska B, Pokrywka A. Selective androgen receptor modulator use and related adverse events including drug-induced liver injury: Analysis of suspected cases. Eur J Clin Pharmacol. 2024;80(2):185-202.
   PMID 38059982 · doi:10.1007/s00228-023-03592-3 · PMC10847181
5. Simitsidellis I, Esnal-Zuffiaure A, Kelepouri O, O'Flaherty E, Gibson DA, Saunders PTK. Selective androgen receptor modulators (SARMs) have specific impacts on the mouse uterus. J Endocrinol. 2019;242(3):227-239.
   PMID 31319382 · doi:10.1530/JOE-19-0153 · PMC6690265
6. Solomon ZJ, Mirabal JR, Mazur DJ, Kohn TP, Lipshultz LI, Pastuszak AW. Selective Androgen Receptor Modulators: Current Knowledge and Clinical Applications. Sex Med Rev. 2019;7(1):84-94.
   PMID 30503797 · doi:10.1016/j.sxmr.2018.09.006 · PMC6326857
7. Thevis M, Geyer H, Kamber M, Schänzer W. Detection of the arylpropionamide-derived selective androgen receptor modulator (SARM) S-4 (Andarine) in a black-market product. Drug Test Anal. 2009;1(8):387-92.
   PMID 20355219 · doi:10.1002/dta.91
8. Thevis M, Thomas A, Fusshöller G, Beuck S, Geyer H, Schänzer W. Mass spectrometric characterization of urinary metabolites of the selective androgen receptor modulator andarine (S-4) for routine doping control purposes. Rapid Commun Mass Spectrom. 2010;24(15):2245-54.
   PMID 20623476 · doi:10.1002/rcm.4637
9. U.S. Food and Drug Administration. Consumer updates and warning letters on body-building products containing SARMs. Regulatory context.
   https://www.fda.gov/
10. World Anti-Doping Agency. Prohibited List — S1 Anabolic Agents (selective androgen receptor modulators).
    https://www.wada-ama.org/
11. NIDDK LiverTox. Selective Androgen Receptor Modulators (SARMs). NCBI Bookshelf NBK619971.
    https://www.ncbi.nlm.nih.gov/books/NBK619971/
12. ClinicalTrials.gov. Protocol inventory via API v2; not peer-reviewed results.
    https://clinicaltrials.gov/
13. PubChem compound summary pages used for identity cross-checks.
    https://pubchem.ncbi.nlm.nih.gov/